Effect of Psilocybin on Empathy and Moral Decision-Making

Thomas Pokorny, MSc; Katrin H. Preller, PhD; Michael Kometer, PhD; Isabel Dziobek, PhD; Franz X. Vollenweider, MD

Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland (Mr Pokorny, and Drs Preller, Kometer, and Vollenweider); Heffter Research Center Zurich, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland (Mr Pokorny, and Drs Preller, Kometer, and Vollenweider); Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Berlin, Germany (Dr Dziobek).

Correspondence: Thomas Pokorny, MSc, Neuropsychopharmacology and Brain Imaging, Heffter Research Center Zurich, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital, Lenggstrasse 31, CH-8032 Zurich, Switzerland (thomas.pokorny@bli.uzh.ch).

Abstract

Background: Impaired empathic abilities lead to severe negative social consequences and influence the development and treatment of several psychiatric disorders. Furthermore, empathy has been shown to play a crucial role in moral and prosocial behavior. Although the serotonin system has been implicated in modulating empathy and moral behavior, the relative contribution of the various serotonin receptor subtypes is still unknown.

Methods: We investigated the acute effect of psilocybin (0.215 mg/kg p.o.) in healthy human subjects on different facets of empathy and hypothetical moral decision-making using the multifaceted empathy test (n = 32) and the moral dilemma task (n = 24).

Results: Psilocybin significantly increased emotional, but not cognitive empathy compared with placebo, and the increase in implicit emotional empathy was significantly associated with psilocybin-induced changed meaning of percepts. In contrast, moral decision-making remained unaffected by psilocybin.

Conclusions: These findings provide first evidence that psilocybin has distinct effects on social cognition by enhancing emotional empathy but not moral behavior. Furthermore, together with previous findings, psilocybin appears to promote emotional empathy presumably via activation of serotonin 2A/1A receptors, suggesting that targeting serotonin 2A/1A receptors has implications for potential treatment of dysfunctional social cognition.

Keywords: empathy, moral decision-making, psilocybin, serotonin, 5-HT2A/1A receptors

Introduction

Empathy and moral behavior are fundamental components of human relationships and important for a well-functioning society (Decety and Cowell, 2014). They have been conceptually linked, and it is thought that empathy plays a crucial role in moral and prosocial behavior (Eisenberg, 2000). Both topics have undergone a renaissance in psychological and neuroscience research in the last decade (Christensen and Gomila, 2012; Decety and Cowell, 2014).

Empathy is a multidimensional construct consisting of at least a cognitive and an emotional component (Blair, 2005). Cognitive empathy describes the ability to adopt and understand the mental or emotional state of another person without...
Significance Statement

Empathy is important for the maintenance of social relationships and plays a crucial role in moral and prosocial behavior. This study investigated the acute effect of the serotonergic hallucinogen psilocybin in healthy human subjects on different facets of empathy and moral decision-making. Psilocybin significantly increased explicit and implicit emotional empathy, compared with placebo, whereas it did not affect cognitive empathy nor moral decision-making. These findings provide first evidence that psilocybin has distinct effects on social cognition by enhancing emotional empathy but not moral behavior. As the psychological effects of psilocybin are primary mediated by serotonin (5-HT) 2A receptor activation and partially modulated by 5-HT1A receptor modulations, our findings suggest the implication of these receptor subtypes in everyday social experience. Therefore, targeting 5-HT2A/1A receptors may have potential beneficial effects in the treatment of mood disorders or psychopathy, which are characterized by deficits in social skills and in particular in the ability to feel with other people.
by 5-HT2A receptor activation (Kometer et al., 2012). For example, psilocybin has been shown to decrease the recognition of negative facial expressions in the reading the mind in the eyes test, an effect that was abolished by ketanserin (Kometer et al., 2012). In addition, psilocybin has also been shown to decrease aggressive behavior in rodents (Kostowski et al., 1972; Uyeno, 1978), suggesting that psilocybin may increase the aversion to harm others. Given the role of serotonin in empathy and moral decision-making and of the 5-HT2A receptor system in the mechanism of action of psilocybin, we hypothesize that psilocybin impairs cognitive empathy for negative stimuli as shown in the reading the mind in the eyes test, whereas it increases emotional empathy. Further, we hypothesize that psilocybin reduces utilitarian choice of action in personal moral dilemmas.

Methods

Participants

Thirty-three healthy human subjects were recruited through advertisements placed at local universities. The MET was conducted in 33 subjects. One participant did not understand the task and had to be excluded from the study; thus, data of 32 participants (17 men, 15 women, mean age 26.72 ± 5.34 years, range 20–38 years) were included in the data analysis. Due to technical reasons, the moral dilemma task (MDT) had been implemented at a later stage during the study and was conducted in 24 subjects immediately after the MET; thus, 24 participants (13 men, 11 women, mean age 26.63 ± 5.33 years; range, 20–38) completed both tasks.

Healthy subjects, aged between 20 and 40 years and willing to refrain from consuming illicit psychoactive drugs from at least 2 weeks before the first experimental session until the last experimental session, were included in the study. All participants underwent a physical examination including electrocardiography and detailed blood and urine analyses (drug screening and pregnancy test) at a screening visit. Pregnant women were identified by urine tests and excluded. A self-report drug questionnaire was used to exclude subjects with a history of drug dependence. To exclude subjects with present or antecedent neuropsychiatric disorders, we used the mini-international neuropsychiatric interview, a structured psychiatric interview (Sheehan et al., 1998), the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (First et al., 1997), and the John Hopkins Symptom Checklist-90 revised (Derogatis and Unger, 2010). A total of 39 subjects were screened whereby 6 subjects did not meet the inclusion/exclusion criteria and therefore were excluded.

Before participating, all participants gave their written consent after having received detailed written and oral information about the aims of the study and the effects and possible risks of psilocybin administration in accordance with the Declaration of Helsinki. The study was approved by the Ethics Committee of the Department of Public Health of the Canton of Zurich, Switzerland, and the use of psilocybin was authorized by the Swiss Federal Office for Public Health, Department of Pharmacology and Narcotics, Berne, Switzerland.

Study Design

This study was designed as a double-blind, randomized, placebo-controlled, within-subject design with 2 experimental sessions. Each participant received psilocybin on one session (0.215 mg/kg body weight, p.o.) and the same amount of identical-looking gelatine capsules containing placebo (mannitol) on the other session. The 2 sessions were separated by at least 10 days.

Study Procedures

Participants were requested to refrain from drinking alcohol the day before the experimental session as well as from drinking alcohol and caffeinated beverages during the experimental days. The absence of acute drug use was assured by urine tests conducted before each experimental session. Participants completed the MET (Dziobek et al., 2008) and the MDT (Harrison et al., 2012) on a computer in a quiet room 160 minutes after substance administration, when the peak perceptual/visual effect of psilocybin had already markedly subsided (Hasler et al., 2004). The Altered States of Consciousness Rating Scale (5D-ASC) (Dittrich, 1998) was used 360 minutes after drug intake when the drug effects have completely subsided to retrospectively quantify the acute subjective effect of psilocybin. The Positive and Negative Affect Schedule (PANAS) (Watson et al., 1988) was applied before and 360 minutes after drug intake to assess the acute effect of psilocybin on mood. Participants were monitored until the drug effects had completely worn off. This was assessed by a trained physician interviewing participants at the end of each session.

Measures

Interpersonal Reactivity Index

The Interpersonal Reactivity Index (IRI) (Davis, 1980, 1983) (German version: Paulus, 2009) is a self-report questionnaire to measure trait empathy and was applied at the screening visit. The short form contains 16 items with a 5-point Likert scale (1 = never; 5 = always). The questionnaire assesses aspects of cognitive and affective empathy by means of 4 subscales: perspective taking (PT) and fantasy (FS) as cognitive empathy subscales, and empathic concern (EC) and personal distress (PD) as affective empathy subscales. PT measures the tendency to adopt the psychological point of view of others, whereas FS measures the disposition to identify with fictional characters. EC captures the other-oriented tendency to experience feelings of compassion, and concern for others, whereas PD assesses self-oriented tendency to feel uneasy and discomfort resulting from the emotions of others.

MET

The MET is a PC-assisted test that assesses cognitive empathy as well as explicit and implicit emotional empathy (Dziobek et al., 2008). It consists of 40 photorealistic stimuli showing people in different emotionally charged situations (20 positive, 20 negative). Each picture is presented 3 times with a different question to assess the 3 different components of empathy. Cognitive empathy is operationalized by the question “What is this person feeling?” and participants have to identify the correct mental state from a list of 4 choices. Explicit emotional empathy is operationalized by the question “How concerned are you for this person?” (negative valence pictures) and “How happy are you for this person” (positive valence pictures) with a 9-point Likert scale (1 = not at all; 9 = very much), respectively. To allow for the measurement of emotional empathy while reducing subjects’ tendencies to give socially desirable answers, an implicit emotional empathy condition was also included, which is operationalized by the question “How calm/ aroused does this picture make you feel?” with a 9-point Likert scale (1 = very calm; 9 = very aroused).
MDT
For the MDT, 2 different sets of matched scenarios containing standard hypothetical moral dilemmas were constructed. They were matched according to previously reported emotional ratings and ratio of utilitarian answers (Koenigs et al., 2007; Harrison et al., 2012). Each set consists of 22 vignettes (adapted from Harrison et al., 2012), illustrating 9 personal dilemmas (thereof 2 inevitable scenarios), 9 impersonal dilemmas, and 4 nonmoral dilemmas. Inevitable scenarios describe situations in which the hypothetical victim dies regardless of the participant’s intervention. Nonmoral dilemmas are scenarios in which the participant chooses between an advantage and a disadvantage for himself without consequences for others. The vignettes were shown on a computer screen, while the dilemmas were presented auditorily via headphones. The participant was asked to take the perspective of a protagonist as all dilemmas are presented in a way that “you” are involved in these scenarios. At the end of each scenario participants were asked to decide if they would choose a utilitarian (sacrifice one or more people to save a higher amount of people) or harm avoidance (no intervention) course of action.

5D-ASC
The 5D-ASC (Dittrich, 1998) was used to assess subjective drug effects in both experimental sessions. The 5D-ASC is a standardized questionnaire comprising 94 items to be shown on visual analogue scales and is an extension of the OAV (Bodmer et al., 1994) containing 66 items. All items from the OAV are incorporated in the 5D-ASC, and the following validated 11 OAV scale scores (Studerus et al., 2010) were computed: experience of unity, spiritual experience, blissful state, insightfulness, disembodiment, impaired control and cognition, anxiety, complex imagery, elementary imagery, audio-visual synesthesia, and changed meaning of percepts. The 5D-ASC scores are expressed as percentage scores of maximum scale values.

PANAS
The PANAS (Watson et al., 1988) was used to assess the self-reported positive and negative affect. Participants are asked to rate the extent to which they experience 20 emotions on a 5-point Likert scale (1 = very slightly or not at all; 5 = extremely). The questionnaire contains 7 arousal-related items (Russell and Carroll, 1999): active, alert, attentive, excited, distressed, jittery, and upset. To measure drug-induced mood changes, the questionnaire was given before (pre) and 360 minutes (post) after drug intake.

Statistical Analysis
Data were analyzed using STATISTICA 8.0 for Windows (StatSoft). For the MET, repeated-measures ANOVAs were computed to analyze data of each empathy component (cognitive empathy, explicit emotional empathy, implicit emotional empathy) with drug (psilocybin, placebo) and valence (positive stimuli, negative stimuli) as within-subject factors and order (placebo first, psilocybin first) as between-subjects factor. For the MDT, the ratio of utilitarian choice (amount of utilitarian answers/total questions) for each category was computed, and a repeated-measures ANOVA was conducted to analyze the ratio of utilitarian choices with moral dilemma category (personal avoidable dilemma, personal inevitable dilemma, impersonal dilemma) and drug (psilocybin, placebo) as within-subject factors and order (placebo first, psilocybin first) as between-subjects factor. To compare the ratio of correct answers in nonmoral dilemma scenarios between the placebo and psilocybin condition, a paired t test was conducted. To control for psilocybin-induced mood changes on the scores of the MET and MDT, ANCOVAs with changes scores (post minus pre psilocybin condition) of positive affect and negative affect from the PANAS as covariates were performed. Independent-samples t tests were performed between psilocybin-experienced (n = 10) and psilocybin-naïve (n = 22) participants to compare their MET and MDT scores in the psilocybin condition. A repeated-measures ANOVA with drug (psilocybin, placebo) and 5D-ASC scale scores (experience of unity, spiritual experience, blissful state, insightfulness, disembodiment, impaired control and cognition, anxiety, complex imagery, elementary imagery, audio-visual synesthesiae, changed meaning of percepts) as within-subject factors were computed for the 5D-ASC ratings. A repeated-measures ANOVA with drug (psilocybin, placebo), time (pre, post), and scale scores (positive affect, negative affect) as within-subject factors were computed for the PANAS scores. Tukey posthoc comparisons followed significant main effects or interactions in the ANOVAs. In case of significant drug effects on outcome measures, change scores were computed (psilocybin minus placebo). To test the potential role of increased arousal on significant outcome measures, an arousal change score (post minus pre drug administration) from the mean of the 7 arousal-related PANAS items (Russell and Carroll, 1999) was computed. A moderator analysis was conducted to ascertain whether the relationship between changed meaning of percepts change scores and implicit emotional empathy change scores is influenced by arousal. To represent the interaction between changed meaning of percepts and arousal, the variables were first centered and then multiplied together. PANAS scores of one subject could not be analyzed due to missing data. Finally, the potential effects of altered states of consciousness (5D-ASC scales change scores), mood change (PANAS post minus pre psilocybin condition), and trait empathy (IRI subscales) on significant outcome measures were explored by means of multiple regression analyses using the backward stepwise method. The confirmatory statistical comparisons of all data were carried out on a significance level set at P < .05 (2-tailed).

RESULTS

IRI
Participants’ scores of the 4 IRI subscales are presented in Table 1.

| IRI subscale                | Mean | SD  | Min | Max |
|----------------------------|------|-----|-----|-----|
| Perspective taking (4–20)  | 15.19| 2.18| 9   | 19  |
| Fantasy (4–20)             | 12.56| 3.23| 6   | 19  |
| Empathic concern (4–20)    | 13.84| 2.41| 9   | 20  |
| Personal distress (4–20)   | 08.69| 2.58| 5   | 15  |
PANAS

There was a significant drug × time × scale interaction ($F(1,30)=6.58$, $P<.05$), a significant drug × time interaction ($F(1,30)=17.34$, $P<.001$), and a significant main effect of scale ($F(1,30)=313.64$, $P<.0001$), indicating that ratings on the positive affect scale were higher than on the negative affect scale. Posthoc tests revealed that positive affect ratings were significantly increased under psilocybin ($P<.05$), but not negative affect ratings ($P>.8$), whereas placebo did not lead to significant changes in positive affect ($P>.2$) nor negative affect ($P>.8$) ratings (Figure 1b). There was a significant difference in the change

Figure 1. Psychological effects of psilocybin. (A) Scores of the Altered States of Consciousness Rating Scale (SD-ASC) scales ($n=32$). Psilocybin significantly increased all scale scores compared with placebo (all $P<.05$), except for anxiety ($P>.8$). (B) Scores of the Positive and Negative Affect Schedule (PANAS) ($n=31$). Mood states compared from pre to post (360 minutes after drug intake). Psilocybin significantly increased positive mood ($P<.05$) but not negative mood ($P>.8$), whereas placebo had no effects on the mood scales (all $P>.2$). Data are expressed as mean ± SEM. *$P<.05$, **$P<.0001$.\n

of arousal level between placebo ($M=-0.07; SD=0.32$) and psilocybin ($M=0.25; SD=0.39$) conditions ($t(31)=-3.96; P<.001$).

**MET**

A significant main effect for drug ($F(1,30)=7.74, P<.01$) revealed that psilocybin increased explicit emotional empathy compared with placebo (Figure 2a). The interaction drug $\times$ valence on explicit emotional empathy was not significant ($F(1,30)=2.97, P>.09$). Neither the interaction drug $\times$ valence $\times$ order ($F(1,30)=1.98, P>.1$) nor the interaction drug $\times$ order ($F(1,30)=3.83, P>.07$) was significant. There was no significant main effect for valence ($F(1,30)=0.11, P>.7$) or order ($F(1,30)=2.51, P>.1$). For implicit emotional empathy, a significant main effect for drug ($F(1,30)=4.77, P<.01$) and valence ($F(1,30)=5.77, P<.01$) was observed. The interaction drug $\times$ valence $\times$ order ($F(1,30)=2.48, P>.1$) was not significant. There was no significant main effect for order ($F(1,30)=1.21, P>.2$). For cognitive empathy, no significant effects were observed. The interaction drug $\times$ valence $\times$ order ($F(1,30)=1.69, P>.2$) was not significant.

**Figure 2.** Multifaceted empathy test (MET). (A) Psilocybin significantly increased the mean rating of explicit and implicit emotional empathy (each $P<.01$) compared with placebo regardless of the valence of the stimuli. (B) No significant effect of psilocybin on the mean of correct answers of cognitive empathy ($P>.2$) compared with placebo were found. In general, participants made significantly more mistakes for negative stimuli than positive stimuli ($P<.05$). Data are expressed as mean ± SEM in 32 subjects. *$P<.05$.
P<.05) revealed that psilocybin increased implicit emotional empathy compared with placebo (Figure 2a). The interaction drug x valence was not significant (F(1,30)=0.00, P>.9). Neither the interaction drug x valence x order (F(1,30)=0.01, P>.9) nor the interaction drug x order (F(1,30)=2.03, P>.1) was significant. There was no significant main effect for valence (F(1,30)=1.05, P>.3), nor order (F(1,30)=3.40, P>.07). There was no significant drug x valence x order interaction (F(1,31)=0.51, P>.4) nor drug x valence interaction (F(1,30)=0.84, P>.3) for cognitive empathy and no significant main effect for drug (F(1,30)=1.45, P>.2). There was a significant drug x order interaction (F(1,30)=5.17, P<.05). Posthoc tests revealed that participants had slightly higher scores in their second test session compared with the first test session independently of drug condition and administration order, as there were neither significant differences in the ratings between drug conditions, nor between administration order (all P>.08). A significant main effect for valence (F(1,30)=6.58, P<.05) revealed that participants made more mistakes on negative than positive stimuli independent of drug condition (Figure 2b). There was no significant main effect for order (F(1,30)=0.01, P>.9). When adding positive or negative mood as a covariate in the analyses, all results remained the same, except for implicit emotional empathy when controlling for positive mood (F(1,30)=2.62, P>.11). Further, independent-samples t tests revealed no significant differences for psilocybin-experienced and psilocybin-naïve participants in the MET scores (all P>.05) in the psilocybin condition.

Associations between MET Change Scores and 5D-ACS Change Scores, PANAS Change Score and IRI

Multiple linear regression analysis revealed that 5D-ASC scale scores explain a significant amount of the variance in the increase of implicit emotional empathy scores (F(1,31)=11.23, P<.01, R²=·27, R²(Adjusted)=·24). The analysis showed that only changed meaning of percepts scores significantly predict the increase of implicit emotional empathy scores (Beta=·52, t(31)=·335, P<.01). No significant results were obtained when the analysis was performed for explicit emotional empathy scores. As the scale changed meaning of percepts and implicit emotional empathy both contain questions regarding arousal, we tested if this relationship was moderated by arousal as measured with the PANAS. Changed meaning of percepts change scores and arousal were entered in the first step of the regression analysis. The model explained a significant amount of the variance in the increase of implicit emotional empathy scores (F(2,29)=5.31, P<.05, R²=·27, R²(Adjusted)=·22). It was found that changed meaning of percepts (Beta=·47, t(29)=2.60, P<.05) significantly predicted the increase in implicit emotional empathy but not arousal (Beta=·09, t(29)=0.47, P>.6). In the second step of the regression analysis, the interaction term between changed meaning of percepts and arousal was entered. This model explained a significant amount of the variance in the increase of implicit emotional empathy scores (F(3,28)=4.18, P<.05, R²=·31, R²(Adjusted)=·24). The analysis shows that only changed meaning of percepts scores significantly predict the increase of implicit emotional empathy scores (Beta=·47, t(28)=2.64, P<.05), but neither arousal (Beta=·07, t(28)=0.38, P>.7) nor the interaction term (Beta=·20, t(28)=1.30, P>.2). Thus, arousal was not a significant moderator of the relationship between changed meaning of percepts and implicit emotional empathy. To investigate if IRI subscale scores or the change scores of the PANAS predict the increase in emotional empathy scores, separate multiple linear regression analyses for explicit and implicit emotional empathy were performed with IRI subscale scores and PANAS scores as predictors using the backward stepwise method. No significant models were obtained (all P>.05).

MDT

There was no significant drug x category interaction (F(2,44)=0.97, P>.3). Neither the drug x category x order interaction (F(2,44)=0.94, P>.4), nor the drug x order interaction (F(1,22)=0.91, P>.3) was significant. There was no significant main effect for drug (F(1,22)=0.37, P>.5), no significant main effect for order (F(1,22)=0.02, P>.8), and no significant main effect for category (F(2,44)=2.77, P>.08) for moral dilemmas (Figure 3). In the nonmoral dilemma scenarios, there was a significant difference between the scores for placebo (M=0.99; SD=0.05) and psilocybin.

Figure 3. Mean ratio of utilitarian choices in 3 different moral dilemma categories from the moral dilemma task (MDT). No effects of psilocybin on moral dilemmas were found. Categories: personal moral avoidable (PM AV), personal moral inevitable (PM IN), impersonal moral (IPM). Data are expressed as mean ± SEM in 24 subjects.
and psilocybin (M=0.91; SD=0.16) condition; t(23)=2.98, P<.01), revealing that participants gave more incorrect answers in the psilocybin condition. When adding positive or negative mood as a covariate in the analyses, all results remained the same. Further, independent-samples t tests revealed no significant differences for psilocybin-experienced and psilocybin-naïve participants in the MDT scores (all P>.1) in the psilocybin condition.

Discussion

Psilocybin significantly increased explicit and implicit emotional empathy independent of stimuli valence. The increase in implicit emotional empathy was related to alterations in meaning of percepts but not trait empathy. There was no significant change in cognitive empathy between placebo and psilocybin. Although psilocybin led to an increase of emotional empathy, no significant difference in decision-making on hypothetical moral dilemmas was found between placebo and psilocybin.

The present finding suggests that 5-HT2A and 5-HT1A receptor systems may be important in the experience of emotional empathy regardless of the emotional valence of the stimuli. Interestingly, previous work has shown that psilocybin modulates the processing and recognition of negative social and nonsocial stimuli, presumably via 5-HT2A and/or 5-HT1A receptor activation (Komter et al., 2012; Schmidt et al., 2013; Bernasconi et al., 2014; Kraehenmann et al., 2014; Preller et al., 2016). Specifically, it has been shown that activation of 5-HT2A receptors is implicated in early encoding and recognition of negative facial expressions (Komter et al., 2012; Schmidt et al., 2013), whereas the 5-HT1A receptor activation seems to influence later processing of both negative and positive facial expressions (Komter et al., 2012; Schmidt et al., 2013; Bernasconi et al., 2014, 2015). Taken together, the present results extend these findings and suggest that the 5-HT2A receptor and possibly also the 5-HT1A receptor are not only implicated in the processing of social and nonsocial emotional stimuli but that they may also be involved in sharing the emotional state of another person (implicit emotional empathy) and the experience of sympathy and prosocial attitudes towards others (explicit emotional empathy).

Furthermore, cognitive empathy remained unaffected by psilocybin, indicating that participants completed the task attentively and correctly. In contrast to emotional empathy, which measures one’s current experience of the emotional state of another person, cognitive empathy/Theory of Mind requires the ability to correctly identify the other person’s emotions. It is possible that emotional empathy in contrast to cognitive empathy is dependent on state variables and may therefore be manipulated more easily whereas it probably takes more time to acquire new cognitive empathy skills.

The 5D-ASC scale score changed meaning of percepts assessed a change in the significance of objects or the surroundings and significantly predicted the increase in implicit emotional empathy scores in the psilocybin condition. Some items of this 5D-ASC scale also refer to a change in the relationship between the observer and the observed objects or the environment. This is reflected for example by the item “Objects around me engaged me emotionally much more than usual”. Such an increased emotional engagement seems to be reflected in the boosted implicit emotional empathy ratings in the present study, indicating that the increased sense of significance may not solely refer to surrounding objects but also to the emotional state of other persons. Although psilocybin significantly increased participant’s arousal scores on the PANAS, the relationship between implicit emotional empathy and changed meaning of percepts was not moderated by arousal. It is noteworthy that the acute mood enhancing effects of psilocybin did not significantly predict the increase in emotional empathy. However, as there was no significant drug effect on implicit emotional empathy when controlling for psilocybin-induced positive affect, we cannot rule out that positive mood was associated with increases in implicit emotional empathy. The psilocybin-induced enhancement of emotional empathy was also not significantly predicted by the trait empathy score of the IRI questionnaire, suggesting that the acute empathy enhancing effect of psilocybin may build up independently from the subject’s baseline or trait empathy level. While the IRI scores in our study sample are comparable with scores from a meta-analysis investigating US college students from 1980 to 2009 (Konrath et al., 2011), the finding that psilocybin’s empathy enhancing effect is independent from trait empathy might be especially relevant for the treatment of psychiatric disorders where the affected patient has low trait empathy levels such as in psychopathy (Blair, 2005). In line with this idea studies in the 1960s suggested that psychedelics such as psilocybin and LSD might be useful in the treatment of psychopaths and criminals (Tenenbaum, 1961; Arends-Hoek, 1963; Leary and Metzner, 1968). Finally it is noteworthy that the implicit and explicit emotional empathy ratings were not associated with the psilocybin-induced visual illusions and hallucinations suggesting that the empathy enhancement is not simply based on visual inaccuracy or disturbances.

A recent fMRI study using the MET showed that emotional empathy in healthy subjects is associated with increased BOLD responses in the brainstem, inferior frontal cortex, posterior superior temporal sulcus, temporal lobe, posterior insular cortex, and posterior cingulate cortex (Dziobek et al., 2011). Whereas prefrontal areas seem to be specifically related to simulating the perspective of others and stepping into their shoes (Mitchell, 2009), regions such as the insula and amygdala appear to be important for enabling the experience of emotional empathy (Blair, 2005; Singer and Lamm, 2009; Dziobek et al., 2011). Given that psilocybin increased neuronal activity as indexed by cerebral glucose metabolism or cerebral blood flow in frontomedial and frontolateral cortices including the anterior cingulate cortex (ACC), the temporomedial cortex, the insula, and the basal ganglia (Vollenweider et al., 1997; Gouzoulis-Mayfrank et al., 1999; Geyer and Vollenweider, 2008) it is conceivable that psilocybin may increase emotional empathy via activation of fronto-temporal and subcortical structures.

The present findings on the effects of psilocybin in the MET endorse the importance of the 5-HT system in empathy. Similar effects were found in previous studies investigating the influence of the 5-HT releasing agent MDMA on the same task (Hysek et al., 2014; Kuypers et al., 2014; Schmid et al., 2014). Specifically, MDMA significantly increased explicit and implicit emotional empathy for all stimuli (Hysek et al., 2014). It is noteworthy that neither oxytocin nor pretreatment with the 5-HT1A receptor antagonist pindolol modulated the empathogenic effects of MDMA (Kuypers et al., 2014). Moreover, a recent study showed that LSD, which acts as an agonist at multiple 5-HT and dopamine receptor sites (Passie et al., 2008), dose-dependently increased explicit and implicit emotional empathy, but in contrast to the present findings with psilocybin, LSD in addition impaired cognitive empathy (Dolder et al., 2016). As the psychological effects of psilocybin are primarily mediated via 5-HT2A receptor activation and partially modulated by 5-HT1A receptor manipulations (Vollenweider et al., 1998; Carter et al., 2007; Komter et al., 2012; Pokorny et al., 2016), both these 5-HT receptor sites may be crucially implicated in the generation of
emotional empathy. However, given that psilocybin acts also on other 5-HT receptor subtypes, further psilocybin studies in combination with selective 5-HT receptor antagonists are warranted to examine the relative contribution of specific 5-HT receptor subtypes on empathy. Although psilocybin also has downstream effects on the dopamine system (Vollenweider et al., 1998; Vollenweider et al., 1999; Halberstadt and Geyer, 2001), an involvement of the dopamine system in the current results is unlikely since administration of the dopamine reuptake inhibitor methylphenidate did not lead to increased empathy ratings in the MDT (Schmid et al., 2014).

Whereas psilocybin increased emotional empathy, it did not affect moral decision-making in any dilemma condition in the MDT. Neuroimaging studies revealed that moral decision-making and empathy are mediated by overlapping networks (Greene et al., 2001; Moll et al., 2002; Greene et al., 2004; Eslinger et al., 2009; Decety et al., 2012), but they also have distinct neuronal correlates (Bzdok et al., 2012). Our finding is well in line with the observation that the serotonin-releasing agent MDMA increased emotional empathy but had no effects on moral judgment in moral dilemma tasks (Schmid et al., 2014). Further, a meta-analysis of fMRI and PET studies investigating the relationship between morality and empathy revealed that affective sharing is unlikely involved during moral decisions (Bzdok et al., 2012).

However, our finding is somewhat surprising given that manipulating the serotonergic tone by a single dose of the serotonin reuptake inhibitor citalopram was reported to lead to harm avoidance in the judgment of personal moral dilemmas (Crockett et al., 2010) and to an aversion for painful electric shocks for oneself and others (Crockett et al., 2015). However this apparent discrepancy may be explained by the fact that Crockett et al. (2010) had examined moral judgments (“Is it acceptable to…?”), whereas we investigated moral decision-making with a choice of action (“Would you…?”) condition. A recent study investigating whether evaluative judgments and choices of action differ when people make decisions on dilemmas involving moral issues suggests that judgment and choice of action are mediated, at least in part, by distinct psychological processes (Tassy et al., 2013), which in turn rely on different neural underpinnings (Tassy et al., 2012). Specifically, using identical dilemma tasks it has been suggested that moral judgment is linked to the functional integrity of the right dorsolateral prefrontal cortex, whereas moral action choice may mainly rely on ventromedial prefrontal cortex function (Cima et al., 2010; Tassy et al., 2012). Taken together, these findings and the dissociable effects of psilocybin on empathy and choice of action suggest that the 5-HT2A/1A receptor system may not be involved in moral decision-making. However, it may also be possible that higher doses of psilocybin are needed to alter the functional integrity of the neuronal networks underlying social moral decisions and choices of action.

Furthermore, it is also noteworthy that personal moral scenarios involve emotionally salient violent acts. Such scenarios activate brain regions implicated in emotional processing, including visual pathways and the amygdala (Greene et al., 2001, 2004). Psilocybin has been shown to reduce the neuronal response to social exclusion in the ACC (Preller et al., 2016) and to lead to a decreased amygdala reactivity to threatening stimuli (Kraehenmann et al., 2014). Thus, it is possible that emotionally loaded personal moral scenarios were less emotionally salient in the psilocybin condition and therefore psilocybin did not enhance aversive emotional reactions to harm others as it was found with citalopram (Crockett et al., 2010).

Although participants made significantly more errors in nonmoral dilemmas under psilocybin than under placebo, the error rate in the psilocybin condition (9%) remained very low as well. We are therefore confident that participants could complete the task after psilocybin administration. However, we cannot rule out that this increase could be due to tiredness, as the task was run as the last test of the session. Therefore, it is possible that deficits in attention may have masked potential effects in the MDT.

In conclusion, whereas moral decision-making was unaffected by psilocybin, the results from the MET indicate that psilocybin enhances emotional empathy but not the cognitive component of empathy. This finding highlights the possible role of 5-HT2A/1A receptors in everyday social experience. Therefore, 5-HT2A/1A receptor agonists may have potential beneficial effects in the treatment of mood disorders or psychopathy, which are characterized by deficits in social skills and in particular in the ability to feel with other people.

Acknowledgments

We thank the study physician Dr. med. Milan Scheidegger for his work and Dr. Christoph Korn for his technical assistance.

This work was supported by the Heffter Research Institute (grant no. 1-190413) and the Swiss Neuromatrix Foundation (grant no. 2015-0102).

Statement of Interest

None.

References

Arendsen-Hein GW (1963) LSD in the treatment of criminal psychopaths. In: Hallucinogenic drugs and their psychotherapeutic use (Croquet RW, Sandison RA, Walk A, eds). London: H. K. Lewis & Co. Ltd.

Barron-Cohen S (2012) Zero degrees of empathy: A new theory of human cruelty. London: Penguin.

Bartels DM, Pizarro DA (2011) The misallocation of morals: antisocial personality traits predict utilitarian responses to moral dilemmas. Cognition 121:154–161.

Bersnacsoni F, Schmidt A, Pokorny T, Kometer M, Seifritz E, Vollenweider FX (2014) Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin. Cereb Cortex 24:3221–3231.

Bersnacsoni F, Kometer M, Pokorny T, Seifritz E, Vollenweider FX (2015) The electrophysiological effects of the serotonin 1A receptor agonist buspironone in emotional face processing. Eur Neuropsychopharmacol 25:474–482.

Blair RJ (2005) Responding to the emotions of others: dissociating forms of empathy through the study of typical and psychiatric populations. Conscious Cogn 14:698–718.

Bodmer I, Dittrich A, Lamparter D (1994) Aussergewöhnliche Bewusstseinszustände: ihre gemeinsame Struktur und Messung [Altered states of consciousness - Their common structure and assessment]. In: Welten des Bewusstseins (Hofmann R, Eickhoff SB, eds), pp45–58. Berlin, Germany: VWB.

Bzdok D, Schilbach L, Vogele K, Schneider K, Laird AR, Langner R, Eickhoff SB (2012) Parsing the neural correlates of moral cognition: ALE meta-analysis on morality, theory of mind, and empathy. Brain Struct Funct 217:783–796.

Carmona-Perera M, Verdejo-García A, Young L, Molina-Fernández A, Pérez-García M (2012) Moral decision-making in polysubstance dependent individuals. Drug Alcohol Depend 126:389–392.
Eslinger PJ, Robinson-Long M, Realmuto J, Moll J, deOliveira-Eisenberg N (2000) Emotion, regulation, and moral development. 

Dziobek I, Preissler S, Grozdanovic Z, Heuser I, Heekeren HR, Dolder PC, Schmid Y, Müller F, Borgwardt S, Liechti ME (2016) LSD Derntl B, Habel U (2011) Deficits in social cognition: a marker for social cognition in borderline personality disorder. Neuroim....

Crim LA, Broadbent V, Minichiello L, Lee C, Ockene JK (2013) Effects of MDMA on emotion regulation and salience network function in healthy volunteers. Neuroimage 80:63–76.

Crockett MJ, Clark L, Hauser MD, Robbins TW (2010) Serotonin selectively influences moral judgment and behavior through effects on harm aversion. Pro Natl Acad Sci U S A 107:17433–17438.

Cima M, Tonnaer F, Hauser MD (2010) Psychopaths know right from wrong but don’t care. Soc Cogn Affect Neurosci 5:59–67.

Davis MH (1983) Measuring individual differences in empathy: evidence for a multidimensional approach. J Pers Soc Psychol 44:113–126.

Decety J, Cowell JM (2014) The complex relation between morality and empathy. Trends Cogn Sci (Regul Ed) 18:337–339.

Decety J, Michalska KJ, Kinzler KD (2012) The contribution of emotion and cognition to moral sensitivity: a neurodevelopmental study. Cereb Cortex 22:209–220.

Dennl B, Habel U (2011) Deficits in social cognition: a marker for psychiatric disorders? Eur Arch Psychiatry Clin Neurosci 261 Suppl 2:145–149.

Derogatis LR, Unger R (2010) Symptom checklist-90-revised. In: The Corsoni Encyclopedia of Psychology (Weiner IB, Craighead WE, eds). Hoboken, NJ: John Wiley & Sons, Inc.

Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Psychopharmacology 138:31–80.

Dolder PC, Schmid Y, Muller F, Borgwardt S, Liechti ME (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology 41:2638–2646.

Dziobek I, Rogers K, Fleck S, Bahmann M, Heekeren HR, Wolf OT, Convit A (2008) Dissociation of cognitive and emotional empathy in adults with Asperger syndrome using the Multifaceted Empathy Test (MET). J Autism Dev Disord 38:464–473.

Dziobek I, Preisler S, Grozdanovic Z, Heuser I, Heekeren HR, Roepke S (2011) Neuronal correlates of altered empathy and social cognition in borderline personality disorder. Neuroimage 57:539–548.

Eisenberg N (2000) Emotion, regulation, and moral development. Annu Rev Psychol 51:665–697.

Eslinger PJ, Robinson-Long M, Realmuto J, Moll J, deOliveira-Souza R, Tovar-Moll F, Wang J, Yang QX (2009) Developmental frontal lobe imaging in moral judgment: Arthur Benton's enduring influence 60 years later. J Clin Exp Neuropsychol 31:158–169.
Koenigs M, Kruepke M, Zeier J, Newman JP (2012) Utilitarian moral judgment in psychopathy. Soc Cogn Affect Neurosci 7:708–714.

Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX (2012) Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry 72:898–906.

Konrath SH, O’Brien EH, Hsing C (2011) Changes in dispositional empathy in American college students over time: a meta-analysis. Pers Soc Psychol Rev 15:180–198.

Kostowski W, Rewerski W, Piechocki T (1972) II. The effects of some hallucinogens on aggressiveness of mice and rats. Pharmacology 7:259–263.

Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX (2014) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry 78:572–581.

Kypers KP, de la Torre Rafael, Farre M, Yubero-Lahoz S, Dziobek I, Van den Bos Wouter, Ramaekers JC (2014) No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. PLoS ONE e100719.

Leary T, Metzner R (1968) Use of psychedelic drugs in prisoner rehabilitation. Br J Soc Psychiatry 2:27–51.

Mitchell JP (2009) Inferences about mental states. Philos Trans R Soc Lond B Biol Sci 364:1309–1316.

Moll J, Oliveira-Souza R de, Bramati IE, Grafman J (2002) Functional networks in emotional moral and nonmoral social judgments. NeuroImage 16:696–703.

Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 14:295–314.

Paulus C (2009) Der Saarbrücker Persönlichkeitsfragebogen SPF der deutschen Version des Interpersonal Reactivity Index.

Pokorny KH, Kraehenmann R, Vollenweider FX (2016) Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol 26:756–766.

Preller KH, Pokorny T, Hock A, Kraehenmann R, Staempfli P, Seifritz E, Scheidegger M, Vollenweider FX, Stämpfli P (2016) Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci U S A 113:5119–5124.

Russell JA, Carroll JM (1999) On the bipolarity of positive and negative affect. Psychol Bull 125:3–30.

Schmid A, Kometer M, Bachmann R, Seifritz E, Vollenweider F (2013) The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociative effects on structural encoding of emotional face expressions. Psychopharmacology (Berl) 225:227–239.

Shamay-Tsoory S, Harari H, Szepsenwol O, Levkovitz Y (2009) Neuropsychological evidence of impaired cognitive empathy in euthymic bipolar disorder. J Neuropsychiatry Clin Neurosci 21:59–67.

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22–33.

Singer T, Lamm C (2009) The social neuroscience of empathy. Ann N Y Acad Sci 1156:81–96.

Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE 5:e12412.

Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol (Oxford) 25:1434–1452.

Tassy S, Oullier O, Duclos Y, Coulou O, Mancini J, Deruelle C, Attarian S, Felician O, Wicker B (2012) Disrupting the right prefrontal cortex alters moral judgement. Soc Cogn Affect Neurosci 7:282–288.

Tassy S, Oullier O, Mancini J, Wicker B (2013) Discrepancies between judgment and choice of action in moral dilemmas. Front Psychol 4:250.

Tenenbaum B (1961) Group therapy with LSD-25. (A preliminary report). Dis Nerv Syst 22:459–462.

Uyeno ET (1978) Effects of psychodysleptics on aggressive behavior of animals. Mod Probl Pharmacopsychiatry 13:103–113.

Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropharmacology 16:357–372.

Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9:3897–3902.

Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bieber A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuropsychopharmacology 20:424–433.

Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54:1063–1070.